Xtant Medical Holdings, Inc. (XTNT) Stock Analysis and Metrics

Xtant Medical Holdings

NYSE: XTNT

$0.43 ▼ 0.00 (-0.30%)

At close: Jul 24, 2026 · 3:58 PM UTC

Financial Ratios

Market Cap5.69 Mn

P/E12.06

Div. Yield0.00

ROIC (Qtr)0.00

Total Debt (Qtr)21.88 Mn

Add ratio to table…

About

Xtant Medical Holdings, Inc. is a global medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant fixation systems to facilitate spinal fusion in complex spine, deformity, and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. In addition, the company’s biologics are applied in trauma, foot and ankle, sports medicine, total joint, and several surgical repair and wound care indications.

The company generates revenue primarily from the sale of its orthobiologics products and spinal implant fixation systems to hospitals, surgery centers, and other healthcare facilities. Revenue is also derived from license agreements, such as the one time payments and royalties received for the distribution of its synthetic and biologic grafts under partner brands. Xtant sells its products in the United States through a network of independent commissioned sales agents and stocking distributors, supported by a national accounts program that provides access to integrated delivery networks and group purchasing organizations. Internationally, the company relies on distribution partners in Europe, Canada, Mexico, South America, and select Pacific region countries to market its offerings.

The company operates through the following segments.

• Orthobiologics: This segment designs, develops, and commercializes a range of biologics including demineralized bone matrix, synthetic bone grafts, viable bone allografts, amniotic membrane products, and collagen powders for use in spinal fusion, trauma, sports medicine, and wound care applications.

• Spinal Implant: This segment designs, develops, and commercializes spinal fixation systems such as cervical plating, thoracolumbar pedicle screw systems, interbody spacers, and sacroiliac joint devices for use in degenerative, deformity, trauma, and tumor related spinal procedures.

Xtant Medical Holdings, Inc. competes in the orthobiologics and spinal implant markets against large medical device corporations and specialized biologics firms. Key competitors include Medtronic plc, Johnson & Johnson, Bioventus Inc., Globus Medical, Inc., OrthoFix Medical Inc., Alphatec Holdings, Inc., Highridge Inc., SI-Bone Inc., as well as tissue banks such as AlloSource International, Inc., LifeNet Health, and MTF Biologics. The company’s competitive advantages stem from its broad product portfolio, extensive patent coverage, established relationships with group purchasing organizations, and a dedicated sales force that reaches both independent surgeons and integrated delivery networks.

Xtant serves orthopedic spine surgeons, neurosurgeons, and other physicians who perform spinal, trauma, and wound care procedures. Its customers include hospitals, ambulatory surgery centers, and integrated delivery networks that purchase products through group purchasing organizations. Specific group purchasing organization names disclosed in the filing are Vizient, Premier, and HealthTrust Purchasing Group. Internationally, the company distributes its products via partners in Europe, Canada, Mexico, South America, and selected Pacific region countries.

Investment Thesis

▲ Bull case

Xtant Medical has significantly strengthened its balance sheet through the divestiture of non core Coflex and CoFix assets which generated approximately twenty one point four million dollars in total proceeds. This cash infusion has allowed the company to reduce long term debt to roughly eleven point two million dollars while increasing cash reserves to over twenty two million dollars after the February 2026 note receipt. The improved liquidity position provides flexibility to fund internal research and development without needing additional external financing. A stronger balance sheet also lowers financial risk and supports potential future strategic acquisitions or shareholder returns.
The company’s strategic shift toward higher margin biologics is evident in the gross margin improvement from fifty eight point two% in full year 2024 to sixty two point nine% in full year 2025. This margin expansion was driven by a favorable sales mix and greater scale from the core biologics portfolio. New product launches such as nanOss Strata and Trivium Shaped are designed to capture additional share in the growing orthobiologics market. Continued innovation in biologics should sustain margin expansion and drive long term profitability.
The exclusive U S distribution agreement for Dilon Technologies HEMOBLAST Bellows opens access to an estimated two billion dollar global hemostasis market. Integration of Dilon’s approximately twenty person U S sales team expands Xtant’s direct commercial reach and enhances cross selling opportunities with its existing biologics portfolio. Early traction from this partnership contributed to the upward revision of full year 2026 revenue guidance from ninety five to ninety nine million to one zero one to one zero five million. The hemostatics business offers a high growth complementary avenue that could accelerate revenue expansion beyond core spinal and wound care products.
Xtant reported positive net income of five million dollars and adjusted EBITDA of sixteen point three million dollars for the full year 2025 marking a clear turnaround from the prior year losses. The company also generated operating cash flow of twelve point five million dollars in 2025 indicating that earnings are translating into real cash generation. Management expects to be free cash flow positive in 2026 given the current cash runway and reduced debt burden. Consistent free cash flow generation would enable the company to self fund growth initiatives and potentially return capital to shareholders.
The launch of nanOss Strata utilizes hydroxycarbonapatite which has higher solubility than traditional hydroxyapatite and is designed to closely mimic human bone structure. This technological advantage aims to improve osteoconductivity and enhance cellular activity potentially leading to better clinical outcomes and surgeon adoption. Early commercial availability through the nationwide distribution network should facilitate rapid market penetration. If the product gains traction it could become a meaningful contributor to the biologics revenue stream and differentiate Xtant from competitors.

Xtant Medical has significantly strengthened its balance sheet through the divestiture of non core Coflex and CoFix assets which generated approximately twenty one point four million dollars in total proceeds. This cash infusion has allowed the company to reduce long term debt to roughly eleven point two million dollars while increasing cash reserves to over twenty two million dollars after the February 2026 note receipt. The improved liquidity position provides flexibility to fund internal research and development without needing additional external financing. A stronger balance sheet also lowers financial risk and supports potential future strategic acquisitions or shareholder returns.
The company’s strategic shift toward higher margin biologics is evident in the gross margin improvement from fifty eight point two% in full year 2024 to sixty two point nine% in full year 2025. This margin expansion was driven by a favorable sales mix and greater scale from the core biologics portfolio. New product launches such as nanOss Strata and Trivium Shaped are designed to capture additional share in the growing orthobiologics market. Continued innovation in biologics should sustain margin expansion and drive long term profitability.
The exclusive U S distribution agreement for Dilon Technologies HEMOBLAST Bellows opens access to an estimated two billion dollar global hemostasis market. Integration of Dilon’s approximately twenty person U S sales team expands Xtant’s direct commercial reach and enhances cross selling opportunities with its existing biologics portfolio. Early traction from this partnership contributed to the upward revision of full year 2026 revenue guidance from ninety five to ninety nine million to one zero one to one zero five million. The hemostatics business offers a high growth complementary avenue that could accelerate revenue expansion beyond core spinal and wound care products.
Xtant reported positive net income of five million dollars and adjusted EBITDA of sixteen point three million dollars for the full year 2025 marking a clear turnaround from the prior year losses. The company also generated operating cash flow of twelve point five million dollars in 2025 indicating that earnings are translating into real cash generation. Management expects to be free cash flow positive in 2026 given the current cash runway and reduced debt burden. Consistent free cash flow generation would enable the company to self fund growth initiatives and potentially return capital to shareholders.
The launch of nanOss Strata utilizes hydroxycarbonapatite which has higher solubility than traditional hydroxyapatite and is designed to closely mimic human bone structure. This technological advantage aims to improve osteoconductivity and enhance cellular activity potentially leading to better clinical outcomes and surgeon adoption. Early commercial availability through the nationwide distribution network should facilitate rapid market penetration. If the product gains traction it could become a meaningful contributor to the biologics revenue stream and differentiate Xtant from competitors.

▼ Bear case

The company’s revenue profile remains heavily dependent on license and royalty streams that are subject to change in reimbursement policies as evidenced by the cessation of Q code and amniotic membrane license revenue in the Q1 FY26. This loss contributed to the year over year decline in first quarter revenue despite underlying biologics growth. Reliance on such non recurring income creates volatility and makes topline results less predictable. Investors should be cautious about assuming that the biologics segment alone can fully replace the lost license contributions without a material increase in product sales.
Although the divestiture of Coflex and CoFix generated cash it also removed a portion of the company’s historical revenue base that contributed to overall scale. The full year 2026 guidance of one zero one to one zero five million remains below the full year 2025 revenue of one three three point nine million indicating a net contraction in top line. This suggests that the core biologics business may not yet be large enough to fully offset the hardware revenue loss. Continued reliance on divestiture proceeds to sustain cash levels may not be a viable long term strategy.
The HEMOBLAST Bellows distribution agreement introduces execution risk as Xtant integrates a twenty person sales team from Dilon and attempts to penetrate a competitive hemostasis market dominated by larger players. Successful adoption will depend on the ability of the combined sales force to effectively communicate the product’s unique value proposition and secure formulary access. Any delay or failure in gaining traction could limit the expected incremental revenue contribution and weigh on overall growth projections. Additionally the exclusivity arrangement could be terminated by either party introducing further uncertainty.
The company’s gross margin improvement may be partially driven by a favorable product mix that includes higher margin license revenue which is no longer present in 2026. As the license revenue stream diminishes the underlying margin of the pure product business could be lower than reported figures suggest. In addition Xtant recorded a one point three million dollar charge for excess and obsolete inventory related to the Cortera Fixation System launch indicating potential challenges in inventory management. Persistent inventory write downs could erode profitability and signal overestimation of demand for new products.
Xtant continues to rely on a network of independent agents and distributors for a significant portion of its revenue which creates exposure to changes in agent performance or contractual terms. The company’s ability to engage and retain qualified independent distributors is highlighted as a risk factor in its SEC filings. Any disruption in this network could negatively affect sales coverage and increase the cost of acquiring new customers. Building a fully owned direct sales force would require substantial investment and may dilute margins if not executed efficiently.

The company’s revenue profile remains heavily dependent on license and royalty streams that are subject to change in reimbursement policies as evidenced by the cessation of Q code and amniotic membrane license revenue in the Q1 FY26. This loss contributed to the year over year decline in first quarter revenue despite underlying biologics growth. Reliance on such non recurring income creates volatility and makes topline results less predictable. Investors should be cautious about assuming that the biologics segment alone can fully replace the lost license contributions without a material increase in product sales.
Although the divestiture of Coflex and CoFix generated cash it also removed a portion of the company’s historical revenue base that contributed to overall scale. The full year 2026 guidance of one zero one to one zero five million remains below the full year 2025 revenue of one three three point nine million indicating a net contraction in top line. This suggests that the core biologics business may not yet be large enough to fully offset the hardware revenue loss. Continued reliance on divestiture proceeds to sustain cash levels may not be a viable long term strategy.
The HEMOBLAST Bellows distribution agreement introduces execution risk as Xtant integrates a twenty person sales team from Dilon and attempts to penetrate a competitive hemostasis market dominated by larger players. Successful adoption will depend on the ability of the combined sales force to effectively communicate the product’s unique value proposition and secure formulary access. Any delay or failure in gaining traction could limit the expected incremental revenue contribution and weigh on overall growth projections. Additionally the exclusivity arrangement could be terminated by either party introducing further uncertainty.
The company’s gross margin improvement may be partially driven by a favorable product mix that includes higher margin license revenue which is no longer present in 2026. As the license revenue stream diminishes the underlying margin of the pure product business could be lower than reported figures suggest. In addition Xtant recorded a one point three million dollar charge for excess and obsolete inventory related to the Cortera Fixation System launch indicating potential challenges in inventory management. Persistent inventory write downs could erode profitability and signal overestimation of demand for new products.
Xtant continues to rely on a network of independent agents and distributors for a significant portion of its revenue which creates exposure to changes in agent performance or contractual terms. The company’s ability to engage and retain qualified independent distributors is highlighted as a risk factor in its SEC filings. Any disruption in this network could negatively affect sales coverage and increase the cost of acquiring new customers. Building a fully owned direct sales force would require substantial investment and may dilute margins if not executed efficiently.

Geographical Breakdown of Revenue (2025)

Peer Comparison

Companies in the Medical Devices

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	ABT	Abbott Laboratories	201.40 Bn	27.98	4.46	34.05 Bn
2	SYK	Stryker Corp	122.29 Bn	36.60	4.84	14.72 Bn
3	MDT	Medtronic plc	105.01 Bn	21.73	2.89	27.96 Bn
4	BSX	Boston Scientific Corp	64.81 Bn	18.16	3.14	11.03 Bn
5	EW	Edwards Lifesciences Corp	55.28 Bn	2,354.76	8.77	0.60 Bn
6	DXCM	Dexcom Inc	29.06 Bn	29.17	6.03	-
7	PHG	Koninklijke Philips Nv	29.02 Bn	22.06	1.42	9.48 Bn
8	GEHC	GE HealthCare Technologies Inc.	28.27 Bn	14.30	1.35	10.14 Bn

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Geographical Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Geographical Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password